The third episode of Orthocell’s ‘Meet the Board’ video series is now online – featuring Chairman, John Van Der Wielen.
Executive Series | Meet The Board | Professor Fiona Wood AM
In the second instalment of the ‘Meet The Board’ video series, we meet Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, and valued member of the Orthocell Board.
Orthocell Receives Regulatory Approval for Remplir™ in Singapore
Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplir™
Orthocell Reports Second Consecutive Quarter of Record Revenue
Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.
VIDEO | Meet The Board | CEO & MD, Paul Anderson
The first episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring CEO & MD, Paul Anderson.
Launching October 2024 | Meet The Board
As part of a special ‘Meet the Board’ video series launching in October 2024, we are pleased to bring you face to face with the team at the top. Tune in for inspiring insights into their vision for our Company.
Ausbiz | Interview with John Van Der Wielen
Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company’s expansion into Canada with dental bone regeneration product, Striate+, and Orthocell’s strong outlook for revenue growth.
Here’s an excerpt:
“In seven quarters, we’ve had 9% CAGR up quarter on quarter, and we don’t expect that to slow down. In fact, we expect it to increase as we bring on new regulatory approvals. And what we’ve just proven with Canada, it was about eight weeks until we got our first sale, so we expect the exponential growth now to speed up.”
Take a look:
Proactive | Interview with John Van Der Wielen
Following the Company’s announcement last week confirming the first sales of Striate+ in Canada, Orthocell’s Chairman John Van Der Wielen spoke with Proactive’s Tylah Tully about the Company’s swift transition from regulatory approval to sales in the Canadian market, and plans to expand into the Singapore and Brazil markets within the next six to 12 months.
The Australian | Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada
Orthocell’s entry to to the Canadian market with the first sales of Striate+ has been reported in The Australian in the article “Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada”.
The article outlines the swift transition from approval to revenue generation in this new market, and points to Striate+’s strong market acceptance and potential.
Here’s an excerpt:
“Strong sales traction in the existing markets has been driven by BioHorizons’ comprehensive marketing and medical education program, which has effectively informed clinicians about the benefits of Striate+.
This success is further supported by Striate+’s outstanding 98.6% success rate in the post-market clinical study.
Consequently, the product’s high-quality performance is motivating BioHorizons to pursue expansion into other large, attractive markets where they have established accounts and distribution networks.”
First Sales of Striate+™ in New and Significant Market of Canada
Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+™ in the key market of Canada.